Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Pfizer's Genetic-Disease Drug Granted Priority Review By FDA

Drug maker Pfizer Inc. (PFE: Quote) said Wednesday that the U.S. Food and Drug Administration has agreed to a priority review of the company's new drug application or NDA for tafamidis meglumine, an experimental drug to treat a rare genetic disease known as Transthyretin Familial Amyloid Polyneuropathy or TTR-FAP.

TTR-FAP is a progressively fatal genetic neuro-degenerative disease caused by the mutation of the TTR gene. The disease affects about 8,000 patients worldwide.

TTR is a protein secreted by the liver and Pfizer's prospective drug destabilizes the proteins that form amyloid fibrils in the peripheral and autonomic nerves, as well as other organs including the gastrointestinal tract, kidneys and heart.

Pfizer noted that the FDA expects to complete the fast-track review of the drug by June 2012. The European Commission approved tafamidis in November 2011. The drug's trade name in the European Union is Vyndaqel.

Pfizer acquired tafamidis with its purchase of FoldRx Pharmaceuticals, a privately-held drug discovery and clinical development company, in September 2010.

Pfizer has earlier filed an application for the drug with the FDA in February 2011. However, the FDA wrote back to the company in April 2011 about its refusal to file the application, saying that the application was not sufficiently complete to permit a substantive review.

In general, refusal to file is reserved for applications with defects that make the application plainly inadequate or non-reviewable without major repair. An inadequate application may delay the process and may need several cycles of FDA response, letters, meetings and more start up time.

In Wednesday's session, PFE is trading at $21.16, down $0.17 or 0.82 percent on a volume of 4.71 million shares.

Register
To receive FREE breaking news email alerts for Pfizer Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Consumers spent less in July than in the previous month, a surprise retreat that complicates the prevailing belief that the U.S. economic situation is improving. Along with the unexpected drop in spending, government figures released on Friday showed that incomes rose at a slower pace in July than in the previous month. Meanwhile, data on prices indicated that inflation pressures remain tame. India's economy grew faster-than-expected in the three months to June and at the strongest pace in two years, preliminary figures from the Central Statistics Office revealed Friday. Gross domestic product grew 5.7 percent in the April to June quarter, which exceeded economists' forecast for 5.5 percent expansion. The economy grew 4.6 percent in the previous three months. Eurozone inflation slowed as expected in August on falling energy prices giving room for the central bank to support demand and economic recovery without stoking inflation and help the region to create more jobs. The unemployment rate remained unchanged at an elevated level in July. Nonetheless, it was at the lowest since September 2012.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.